Multicenter validation of a machine learning phase space electro-mechanical pulse wave analysis to predict elevated left ventricular end diastolic pressure at the point-of-care

Phase space is a mechanical systems approach and large-scale data representation of an object in 3-dimensional space. Whether such techniques can be applied to predict left ventricular pressures non-invasively and at the point-of-care is unknown. This study prospectively validated a phase space mach...

Full description

Saved in:
Bibliographic Details
Published inPloS one Vol. 17; no. 11; p. e0277300
Main Authors Bhavnani, Sanjeev P., Khedraki, Rola, Cohoon, Travis J., Meine, Frederick J., Stuckey, Thomas D., McMinn, Thomas, Depta, Jeremiah P., Bennett, Brett, McGarry, Thomas, Carroll, William, Suh, David, Steuter, John A., Roberts, Michael, Gillins, Horace R., Shadforth, Ian, Lange, Emmanuel, Doomra, Abhinav, Firouzi, Mohammad, Fathieh, Farhad, Burton, Timothy, Khosousi, Ali, Ramchandani, Shyam, Sanders, William E., Smart, Frank
Format Journal Article
LanguageEnglish
Published United States Public Library of Science 15.11.2022
Public Library of Science (PLoS)
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Phase space is a mechanical systems approach and large-scale data representation of an object in 3-dimensional space. Whether such techniques can be applied to predict left ventricular pressures non-invasively and at the point-of-care is unknown. This study prospectively validated a phase space machine-learned approach based on a novel electro-mechanical pulse wave method of data collection through orthogonal voltage gradient (OVG) and photoplethysmography (PPG) for the prediction of elevated left ventricular end diastolic pressure (LVEDP). Consecutive outpatients across 15 US-based healthcare centers with symptoms suggestive of coronary artery disease were enrolled at the time of elective cardiac catheterization and underwent OVG and PPG data acquisition immediately prior to angiography with signals paired with LVEDP (IDENTIFY; NCT #03864081). The primary objective was to validate a ML algorithm for prediction of elevated LVEDP using a definition of ≥25 mmHg (study cohort) and normal LVEDP ≤ 12 mmHg (control cohort), using AUC as the measure of diagnostic accuracy. Secondary objectives included performance of the ML predictor in a propensity matched cohort (age and gender) and performance for an elevated LVEDP across a spectrum of comparative LVEDP (<12 through 24 at 1 mmHg increments). Features were extracted from the OVG and PPG datasets and were analyzed using machine-learning approaches. The study cohort consisted of 684 subjects stratified into three LVEDP categories, ≤12 mmHg (N = 258), LVEDP 13-24 mmHg (N = 347), and LVEDP ≥25 mmHg (N = 79). Testing of the ML predictor demonstrated an AUC of 0.81 (95% CI 0.76-0.86) for the prediction of an elevated LVEDP with a sensitivity of 82% and specificity of 68%, respectively. Among a propensity matched cohort (N = 79) the ML predictor demonstrated a similar result AUC 0.79 (95% CI: 0.72-0.8). Using a constant definition of elevated LVEDP and varying the lower threshold across LVEDP the ML predictor demonstrated and AUC ranging from 0.79-0.82. The phase space ML analysis provides a robust prediction for an elevated LVEDP at the point-of-care. These data suggest a potential role for an OVG and PPG derived electro-mechanical pulse wave strategy to determine if LVEDP is elevated in patients with symptoms suggestive of cardiac disease.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
Competing Interests: I have read the journal’s policy and authors of this manuscript have the following competing interests. Sanjeev Bhavnani MD is a scientific advisor to Corvista Health and Blumio; consultant to Bristol Meyers Squibb, Pfizer, and Infineon Semiconductor; data safety monitoring board chair at Proteus Digital; has received research support from Scripps Clinic and the Qualcomm Foundation and is member of the healthcare innovation advisory boards at the American College of Cardiology, American Society of Echocardiography, and BIOCOM (all non-profit institutions with all positions voluntary). Jeremiah P. Depta MD reports consulting fees from Edwards Lifesciences LLC, Boston Scientific, V wave Medical Ltd and Abbot. Brett Bennett MD reports payment or honoraria for lecture from Philips. Horace R. Gillins BS, Ian Shadforth EngD, Emmanuel Lange, Abhinav Doomra MScAC, Mohammad Firouzi MSc, Farhad Fathieh PhD, Timothy Burton BComp, Ali Khosousi PhD, Shyam Ramchandani PhD and William E. Sanders Jr. MD report employment by CorVista Health, and stock options in the same. Frank Smart MD reports grants or contracts from Abbot (GUIDE HF clinical trial), NIH / Ohio State (DCM genetic study), Duke Clinical Research (Transform HF), CorVista Health (Pulmonary Hypertension clinical trial), and participation on a Data Safety Monitoring Board or Advisory Board (Abbott Medical; GUIDE-HF Steering committee). All other authors report no disclosures. This does not alter our adherence to PLOS ONE policies on sharing data and materials.
ISSN:1932-6203
1932-6203
DOI:10.1371/journal.pone.0277300